SARASOTA, Fla. , Nov. 9, 2004 (PRIMEZONE) -- eLocity's velocity stocks to watch for today are; Southwestern Medical Solutions, Inc. (Pink Sheets:SWNM), Microsoft Corp. (Nasdaq:MSFT), Novell Inc. (Nasdaq:NOVL) and Vertex Pharmaceuticals Inc. (Nasdaq:VRTX).
Investor may want to check out Southwestern Medical Solutions, Inc. (Pink Sheets:SWNM). Southwestern announced after the closing bell Monday that Physicians STAT Laboratories has requested that SWMS package a specific 9-panel model of its Labguard Accuchec(tm) diagnostic testing device. The Company's proprietary Labguard Accucheck(tm) on-site collection and diagnostic testing technology represents a revolutionary approach that ensures greater safety and convenience for diagnostic testing administrators at an attractive, market-competitive price.
The new 9-panel test will be offered in a variety of formats that will facilitate the screening for of a wide range of components/substances including: Alcohol Use, Allergies, Mold, Blood Type and Cancers.
SWNM currently trades at around .10 a share.
Microsoft Corp. (Nasdaq: MSFT), Novell Inc. (Nasdaq: NOVL)
Monday, software giant Microsoft Corp. (Nasdaq:MSFT) said that it will bring to an end of a decade-long antitrust battle with Novell, Inc. (Nasdaq:NOVL) by agreeing to settle antitrust lawsuits with Novell Inc. and an industry trade group, the Computer and Communications Industry Association. Novell and the trade group agreed to pull out of the legal case against Microsoft in the European Union. Microsoft said that it will pay $536 million in cash to settle the antitrust lawsuit. Novell said that it is also filing a new antitrust suit against Microsoft tied to Novell's WordPerfect software.
MSFT closed Monday's regular trading session at $29.28, down 3 cents, on high volume of 112.8 million shares, while NOVL ended the session at $7.51, on volume of 31.3 million shares.
Vertex Pharmaceuticals Inc. (Nasdaq: VRTX)
Biotech company Vertex Pharmaceuticals Inc. announced Monday that it has initiated a Phase Ib clinical trial for its investigational oral protease inhibitor for the treatment of hepatitis C virus infection, VX-950. The company said that the double-blind, placebo- controlled study will evaluate the tolerability, pharmacokinetics and viral kinetics of multiple ascending doses of VX-950 over a period of up to 14 days.
VRTX closed Monday at $11.18, down 13 cents.
About eLocity Inc: eLocity owns and operates three financial websites for investors.
- PennyPicks.com, http://www.pennypicks.com/. Featuring active message boards for the penny stock trader, rumors and more.
- StockGrid.com, http://www.stockgrid.com/. Visit this site for our daily top stock "GRID Makers." We rank stocks on volume, message board activity, sentiment and trend forecast.
- Bell2Bell.com, http://www.bell2bell.com/. Bell2Bell features news stories, rumors, the InvestBoard and more.
Sign up for FREE at any of the sites above.
The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is here after referred to as "the company". The company is to receive compensation for newsletter services for SWNM. (Public Company). The compensation is one thousand dollars from a non-affiliated third party Geneva Bancorp. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.
The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.
The company relies exclusively on information gathered on the Public Company, such as public filings, press releases and its web sites. Investors should use the information contained in this publication as a starting point for conducting additional research on the Public Company in order to allow the investor to form his or her own opinion regarding the Public Company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.
Investing in the Public Company that this newsletter is providing service for should be reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.
The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.